Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and sex toys.
Popular Articles

New Cortex Study Uncovers How We Recognize What Is True And What Is False
A recent neuroimaging study reveals that the ability to distinguish true from false in our daily lives involves two distinct processes. Previous research relied heavily on the premise that true and false statements are both processed in the left inferior frontal cortex. Carried out by researchers from the Universities of Lisbon and Vita-Salute, Milan, the June Cortex study found that we use two separate processes to determine the subtle distinctions between true and false in our daily lives. Deciding whether a statement is true involves memory; determining one is false relies on reasoning and problem-solving processes.
buy viagra
Major Study Links Malaria Mosquitoes To Amazon Deforestation
In one of the most field-intensive efforts to explore the connection between malaria and tropical deforestation, a team led by Jonathan Patz, a specialist in the link between environment and health at the Nelson Institute for Environmental Studies at the University of Wisconsin-Madison, has established a strong correlation between the extent of forest destruction and the incidence of the Amazon"s most dangerous malaria vector, the mosquito Anopheles darlingi.
News of the day
McGill Conference Examines Impact Of Economic Crisis On The Hungry
The global economic crisis has had a devastating impact on the world"s hungry. In the past year, approximately 100 million people have been added to the ranks of the roughly 1 billion people worldwide considered by the United Nations Food and Agricultural Organization to be undernourished, according to its report issued June 19, 2009.
Public Health

New Data Support Use Of Simple Test To Predict Endometrial Cancer Response To Chemotherapy

New data presented at the 2009 American Society of Clinical Oncologist (ASCO) Annual Meeting support the use of a laboratory test, ChemoFX(R), to help physicians predetermine the effectiveness of chemotherapy in treating a woman"s endometrial cancer. Investigators found a significant correlation between the test results from 405 patient specimens analyzed using ChemoFx and published patient response rates for each chemotherapeutic regimen, suggesting less effective therapies could be eliminated prior to patient administration. Endometrial cancer is the most common gynecologic cancer among women in the United States. "Limiting a patient"s exposure to chemotherapy is important, however determining the appropriate treatment the first time for a woman with endometrial cancer can be challenging," said Dr. Warner K. Huh, MD., Lead Investigator and Associate Professor, Division of Gynecologic Oncology, University of Alabama at Birmingham, "These data suggest a more targeted approach could be achieved by testing the effect of various chemotherapeutic agents on a woman"s tumor before a therapy is administered to the patient, potentially bypassing use of ineffective therapies." Published data suggest that individual patients will only respond to a single chemotherapy agent 30 percent of the time and while combination therapy can increase a patient"s response up to 60 percent, finding the combination that will achieve that response can prove difficult. The unintended consequences of ineffective treatment include, but are not limited to, patient exposure to the toxic aspects of the chemotherapy and delay in the patient receiving potentially beneficial treatments. ChemoFx is a test that quantifies an individual cancer patient"s probable tumor response to various chemotherapeutic and biologic agents -- providing both sensitivity and resistance information. "We are very pleased with the results of this study and the correlation between the test results generated using ChemoFX and published response rates for commonly used chemotherapy," said Dr. Holly Gallion, MD, Vice President Medical Affairs, Precision Therapeutics, Inc., "This is a significant step toward ensuring women receive the most effective chemotherapy, early in the treatment process, with limited exposure to therapies that may provide minimal benefit." About the Study Tumor specimens were collected from December 1, 2007 to July 15, 2008 from 405 consecutive patients with endometrial carcinoma and were tested in vitro for a response using the ChemoFx assay. Tumors were categorized prospectively as responsive (R), intermediately responsive (IR) or nonresponsive (NR) to each drug or combination of drugs tested. The in vitro response rates were compared to reported response rates from clinical trials. The International Federation of Gynecology and Obstetrics (FIGO) stage distribution was 171 stage I patients, 32 stage II patients, 106 stage III patients, 57 stage IV patients, 37 recurrent patients, and 2 unknown patients. The assay was successfully completed for 360 (89 percent) cases. The majority of tumors (73 percent) exhibited varying degrees of responsiveness to different drug(s). No significant difference in response rate was observed between primary and recurrent tumors or between stage I/II and III/IV tumors. In vitro tumor response rates were similar to reported treatment response rates for all treatments except single-agent carboplatin. Investigators concluded that a drug response marker can provide clinically useful information to optimize individual chemotherapy regimens for women with endometrial cancer. About Precision Therapeutics Precision Therapeutics is a diagnostics services company dedicated to providing physicians and patients with actionable clinical information to personalize cancer treatments. Precision Therapeutics is a leader in the development and delivery of treatment support tools that assist physicians and benefit cancer patients. Precision Therapeutics, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009